

09PH  
C174



**Molecular and cellular studies examining the biological  
significance of different isoforms of the receptor tyrosine  
kinase, c-Kit**

**Antony Charles Cambareri**  
B. Sc. (Hons)

Institute of Medical and Veterinary Science

Department of Medicine  
University of Adelaide  
South Australia

A thesis submitted to the University of Adelaide  
in candidature for the degree of Doctor of Philosophy  
October 2004

# Contents

<b>1</b>	<b>INTRODUCTION</b>	<b>1</b>
1.1.	C-KIT - A MEMBER OF THE GROWTH FACTOR RECEPTOR TYROSINE KINASE FAMILY	1
1.1.1.	<i>The Growth Factor Receptor Tyrosine Kinases</i>	1
1.1.2.	<i>Signalling through RTKs</i>	3
1.1.3.	<i>c-Kit in Cancer</i>	6
1.2.	HISTORY OF C-KIT	8
1.2.1.	<i>- The discovery of the c-Kit proto-oncogene</i>	8
1.2.2.	<i>Association of c-Kit with the W locus</i>	10
1.3.	THE LIGAND TO C-KIT: THE LINK BETWEEN W AND SL MUTANT MICE	13
1.4.	BIOCHEMICAL ANALYSIS OF C-KIT - LIGAND BINDING DOMAIN	16
1.5.	LIGAND INDUCED RECEPTOR DIMERISATION	18
1.6.	LIGAND INDUCED RECEPTOR SIGNALLING	20
1.6.1.	<i>SH2</i>	20
1.6.2.	<i>SH3</i>	21
1.6.3.	<i>PH</i>	22
1.6.4.	<i>PTB</i>	23
1.6.5.	<i>Modular Generation of Diversity</i>	23
1.7.	SIGNALLING THROUGH C-KIT	24
1.7.1.	<i>PI3-Kinase</i>	25
1.7.2.	<i>Phospholipase C-<math>\gamma</math>1</i>	26
1.7.3.	<i>RAS-MAPK</i>	27
1.7.4.	<i>Protein Kinase C</i>	28
1.7.5.	<i>Src Family Kinases</i>	29
1.7.6.	<i>Other</i>	29
1.8.	DOWNMODULATION OF C-KIT EXPRESSION/ACTIVATION	30
1.8.1.	<i>PKC</i>	31
1.8.2.	<i>Extracellular domain shedding</i>	32
1.8.3.	<i>Ubiquitination</i>	32
1.8.4.	<i>Phosphatases</i>	33
1.8.5.	<i>Others</i>	34
1.9.	MECHANISMS INDUCING SIGNALLING DIVERSITY BY THE RTK	35
1.9.1.	<i>c-Kit Isoforms</i>	35
1.9.2.	<i>Heterodimerisation</i>	36
1.9.3.	<i>Receptor levels</i>	39
1.10.	AIMS	41
<b>2</b>	<b>MATERIALS AND METHODS</b>	<b>43</b>
2.1.	TISSUE CULTURE	43
2.1.1.	<i>Tissue Culture Media and Solutions</i>	43
2.1.2.	<i>Cytokines and growth factors</i>	46
2.2.	CULTURE MAINTENANCE OF CELLS	47
2.2.1.	<i>Psi 2 cell line maintenance</i>	47
2.2.2.	<i>FDC-P1 cell line maintenance</i>	48
2.2.3.	<i>NIH3T3 cell line maintenance</i>	48
2.2.4.	<i>Maintenance of Myb Immortalised Haemopoietic Cell (MIHC) lines</i>	48
2.2.5.	<i>Maintenance of MO7e</i>	49
2.2.6.	<i>Cryopreservation of Cells</i>	49
2.2.7.	<i>Thawing of Cryopreserved Cells</i>	50
2.2.8.	<i>Cytology, Cytochemistry and Histology</i>	50
2.2.9.	<i>Morphological characterisation of cells</i>	50
2.2.10.	<i>Phenotypic characterisation of cells – esterase staining</i>	51
2.3.	IMMUNOASSAYS	52
2.3.1.	<i>Antibodies</i>	52
2.3.2.	<i>Immunofluorescence Assay</i>	53
2.3.3.	<i>Alkaline Phosphatase Anti-Alkaline Phosphatase Technique</i>	54
2.3.4.	<i>Quantitative confocal microscopy for determination of endogenous <math>\mu</math>SCF levels</i>	56
2.3.5.	<i>Confocal Microscopy – visualisation of receptor internalisation</i>	57
2.4.	ANALYSIS OF CELL SURVIVAL, PROLIFERATION AND GROWTH BY PKH ASSAY	58

2.5.	SATURATION BINDING ANALYSIS (SCATCHARD ANALYSIS)	60
2.6.	PROTEIN ANALYSIS	61
2.6.1.	Preparation of cellular lysates	61
2.6.2.	Immunoprecipitation	62
2.6.3.	Determination of the amount of protein within lysates	62
2.6.4.	Size determination of proteins – SDS PAGE	63
2.6.5.	Transfer of proteins to PVDF	64
2.6.6.	Visualisation of blots	64
2.6.7.	Quantitation of protein bands	65
2.7.	MANIPULATION OF DNA	65
2.7.1.	Restriction Endonuclease Digestion	65
2.7.2.	Electrophoresis of DNA	65
2.7.3.	Size determination and quantitation of DNA fragments	66
2.7.4.	Purification of DNA	67
2.7.5.	Dephosphorylation of DNA	68
2.7.6.	Ligation	69
2.7.7.	Production of chemical competent bacterial cells	69
2.7.8.	Transformation of chemical competent cells	70
2.7.9.	Expansion of plasmid DNA	70
2.7.10.	Polymerase Chain Reaction	72
2.7.11.	Generation of anti-sense murine SCF	73
2.7.12.	Chimaeric c-Kit Generation – Step 1 PCR conditions	74
2.7.13.	Chimaeric c-Kit Generation – Steps 2 and 3	77
2.7.14.	PCR Site Directed Mutagenesis of chimaeric c-Kit cDNA	79
2.7.15.	Q-PCR	81
2.7.16.	Sequencing of DNA	83
2.7.17.	Calcium phosphate transfection into NIH3T3 cells	84
2.7.18.	Retroviral infection of suspension cells by co-cultivation	85
2.8.	MANIPULATION OF RNA	86
2.8.1.	Total RNA Extraction	86
2.8.2.	Quantitation of RNA	87
2.8.3.	Random Oligonucleotide Priming – probe generation	87
2.8.4.	Northern Blot Transfer	88
2.9.	REAGENTS	89
2.9.1.	Immunocytochemistry, Immunohistochemistry and Immunofluorescence Reagents	89
2.9.2.	Reagents For Protein Analysis	91
2.9.3.	Molecular Biology Reagents	93
<b>3</b>	<b>TRANSFORMING POTENTIAL OF C-KIT - EFFECTS OF COPY NUMBER AND ISOFORM</b>	<b>96</b>
3.1.	C-KIT RECEPTOR LEVELS	96
3.2.	ECTOPIC EXPRESSION OF C-KIT IN THE NIH3T3 MODEL: PREVIOUS FINDINGS IN THIS LABORATORY	97
3.2.1.	Overexpression of c-Kit	98
3.2.2.	Transformation potential of Human c-Kit isoforms	98
3.3.	ECTOPIC EXPRESSION OF MURINE C-KIT IN NIH3T3 MODEL	101
3.3.1.	Quantitation of mu c-Kit surface expression	101
3.3.2.	Autocrine stimulation	101
3.3.3.	Human c-Kit Isoforms	103
3.3.4.	Establishment of c-Kit copy number on cell pools	104
3.3.5.	Affinity of isoforms of human c-Kit for SCF	105
3.3.6.	Transformation of NIH3T3 cells expressing c-Kit isoforms	105
3.4.	BIOCHEMICAL ANALYSIS OF HUMAN C-KIT ISOFORMS SIGNALLING	106
3.4.1.	Kinetics of activation of c-Kit isoforms, recruitment of p85 subunit of PI3-K	106
3.4.2.	Internalisation of c-Kit following SCF stimulation	107
3.4.3.	Downstream signalling from c-Kit isoforms	108
3.5.	DISCUSSION	109
3.5.1.	c-Kit receptor levels	109
3.5.2.	Hu-c-Kit isoforms	112
3.5.3.	Biochemical analysis	113

3.5.4.	<i>Future experiments</i> .....	117
<b>4</b>	<b>DEVELOPMENT OF CHIMAERIC C-KIT ISOFORMS FOR EXPRESSION IN NEW MYB IMMORTALISED HAEMOPOIETIC CELL (MIHC) LINES</b> .....	<b>118</b>
4.1.	MYB-IMMORTALISATION OF HAEMOPOIETIC CELLS .....	119
4.1.1.	<i>Myb gene family</i> .....	119
4.1.2.	<i>c-Myb structure</i> .....	120
4.1.3.	<i>Cellular targets of c-Myb</i> .....	123
4.1.4.	<i>c-Myb regulation of proliferation and differentiation</i> .....	123
4.1.5.	<i>Activated c-Myb immortalisation of primitive haemopoietic cells</i> .....	125
4.2.	LYN – A MEMBER OF THE SRC FAMILY OF TYROSINE KINASES .....	125
4.2.1.	<i>Src Family Kinase Structure</i> .....	126
4.3.	LYN AND C-KIT .....	128
4.3.1.	<i>Lyn knockout mice</i> .....	129
4.4.	GENERATION OF HUMAN/MOUSE CHIMAERIC C-KIT.....	130
4.4.1.	<i>Strategy</i> .....	131
4.4.2.	<i>Cloning chi-c-Kit GNNK ± into pBS-SK</i> .....	133
4.4.3.	<i>Mutation corrections</i> .....	134
4.4.4.	<i>Generation of MIHC c57 and Lyn -/- (use of mIL-3)</i> .....	134
4.4.5.	<i>Morphology of MIHC lines</i> .....	137
4.5.	INTRODUCTION OF CHI C-KIT GNNK+/- INTO LYN -/- AND C57 MIHC .....	138
4.6.	RESPONSE OF CHIMAERIC C-KIT TO HUMAN SCF IN C57 AND LYN -/- MIHCs .....	142
4.6.1.	<i>Chimaeric c-Kit Internalisation in response to human SCF</i> .....	142
4.6.2.	<i>Proliferation and Survival in response to Human SCF</i> .....	143
4.7.	CHIMAERIC C-KIT DOWNSTREAM SIGNALLING ANALYSIS- LYN-/- VS C57 MIHCs .....	145
4.8.	DISCUSSION .....	149
4.8.1.	<i>MIHC Generation</i> .....	150
4.8.2.	<i>Cellular responses to exogenous Human SCF</i> .....	152
4.8.3.	<i>Further experiments</i> .....	154
<b>5</b>	<b>ANALYSIS OF C-KIT ISOFORM EXPRESSION IN PRIMITIVE HUMAN HAEMOPOIETIC CELLS</b> .....	<b>156</b>
5.1.	EXPRESSION OF C-KIT ISOFORMS IN PRIMITIVE HAEMOPOIETIC CELLS.....	156
5.2.	G-CSF MEDIATED STEM CELL MOBILISATION – INVOLVEMENT OF C-KIT .....	157
5.3.	ANALYSIS OF GNNK+/- EXPRESSION IN NORMAL BONE MARROW MONONUCLEAR CELLS (MNCs).....	160
5.3.1.	<i>Design and validation of “minor groove binder” (MGB)- TaqMan probes</i> .....	161
5.3.2.	<i>Isolation of Normal Bone Marrow CD34+ subpopulations</i> .....	163
5.3.3.	<i>QPCR analysis of Normal Bone Marrow subsets</i> .....	164
5.4.	ANALYSIS OF GNNK+/- EXPRESSION IN MOBILISED CD34+ CELLS .....	166
5.4.1.	<i>Isolation of Peripheral Blood CD34 positive stem cells</i> .....	166
5.4.2.	<i>QPCR analysis of Peripheral Blood CD34 positive cells</i> .....	167
5.4.3.	<i>Cell surface c-Kit levels in mobilised CD34 stem cells</i> .....	168
5.5.	DISCUSSION .....	170
5.6.	APPENDIX 1 .....	174
5.6.1.	<i>CD34</i> .....	174
5.6.2.	<i>CD33</i> .....	176
5.6.3.	<i>CD38</i> .....	177
5.6.4.	<i>CD19</i> .....	178
5.6.5.	<i>CD61</i> .....	179
5.6.6.	<i>CD7</i> .....	180
5.6.7.	<i>Glycophorin A</i> .....	181
<b>6</b>	<b>GENERAL DISCUSSION</b> .....	<b>182</b>
6.1.	MURINE C-KIT RECEPTOR LEVELS .....	183
6.2.	HU-C-KIT ISOFORMS.....	186
6.2.1.	<i>Biochemical analysis</i> .....	186
6.3.	DEVELOPMENT OF A NEW MODEL TO TEST C-KIT CELLULAR RESPONSES.....	190
6.3.1.	<i>Myb Immortalised Haemopoietic Cell (MIHC) development</i> .....	190
6.3.2.	<i>Cellular responses to exogenous Human SCF by chimaeric c-Kit in MIHC</i> .....	193

6.3.3.	<i>Future directions for MHC model</i> .....	196
6.4.	ISOFORM EXPRESSION.....	196
6.5.	CLOSING COMMENTS.....	199
<b>7</b>	<b>BIBLIOGRAPHY</b> .....	<b>201</b>

## Abstract

c-Kit is a member of the Receptor Tyrosine Kinase Type III family and has four naturally occurring isoforms. The work presented in Chapter 3 utilised full-length human or murine c-Kit cDNA expressed in murine cells. Over-expression of normal c-Kit was capable of contributing to oncogenic transformation. The analysis of human c-Kit isoforms demonstrated dissociation of various indicators of transformation (anchorage independence, loss of contact inhibition, tumourigenicity) in the NIH3T3 cell model.

Biochemical analysis of the c-Kit signalling revealed qualitative and quantitative differences between the GNNK+ and GNNK- c-Kit isoforms. The GNNK- isoform was hyperphosphorylated more extensively and rapidly, and was also more efficiently ubiquitinated and degraded than the GNNK+ counterpart. PI3-K was recruited and activated equally by both isoforms. Phosphorylation of MAPK paralleled that of the c-Kit isoform's phosphorylation.

In Chapter 4, a new model was developed using a chimaeric human extracellular c-Kit/murine transmembrane + intracellular c-Kit. This new molecule, in conjunction with a murine Myb Immortalised Haemopoietic Cell (MIHC) line was used to investigate a number of biological outcomes stimulated by SCF simultaneously. A MIHC line lacking Lyn was also analysed.

Chimaeric c-Kit displayed the same signalling characteristics exhibited by its' full-length human counterpart. The model showed that the GNNK- isoform was superior

in its survival stimulus to GNNK+, but both were equivalent in promoting proliferation. The absence of Lyn reduced the ability of both isoforms to promote survival.

The aim of work in Chapter 5 was to elucidate the expression patterns of the c-Kit isoforms in subsets of normal human haemopoietic cells. Methodology was developed to detect GNNK+/- c-Kit mRNA from rare subsets of cells from bone marrow. As c-Kit is known to be down-modulated in mobilised peripheral blood stem cells, mobilised CD34+ cells were also investigated. In all haemopoietic cells analysed, there was no significant difference in expression patterns of the c-Kit isoforms, with all samples expressing approximately 90% of total c-Kit transcripts as the GNNK- isoform. c-Kit downmodulation observed in mobilisation of CD34+ cells was not influenced at the level of transcription, but at the protein level.